Marshall Urist
Known title: EVP, Research & InvestmentsCIK: 0001838139
Associated companies
Transaction History
| RPRX | ▼ Sell | Open Market | 4,126 | $236K | 10/5/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 4,126 | $239K | 9/28/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 8,252 | $0 | 8/5/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 9,099 | $508K | 7/1/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 9,098 | $502K | 6/24/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 13,684 | $722K | 5/20/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 13,684 | $726K | 5/14/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 18,197 | $0 | 5/6/2026 | View on chart |
| RPRX | ▲ Buy | Grant | 19,970 | $0 | 2/11/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $822K | 1/30/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $805K | 1/23/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $790K | 1/16/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $816K | 1/9/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $770K | 1/2/2026 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $786K | 12/26/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $768K | 12/19/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 20,000 | $766K | 12/16/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 18,242 | $714K | 12/5/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 23,334 | $914K | 12/5/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 23,333 | $932K | 12/1/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 18,242 | $728K | 12/1/2025 | View on chart |
| RPRX | ▼ Sell | Other | 160,000 | $0 | 11/7/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 4,626 | $0 | 11/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 2,772 | $0 | 8/6/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 36,484 | $0 | 5/8/2025 | View on chart |
| RPRX | ▼ Sell | Open Market | 23,333 | $870K | 2/22/2023 | View on chart |
| RPRX | ▼ Sell | Other | 70,000 | $0 | 2/17/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 19,734 | $852K | 7/26/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 3,600 | $155K | 7/25/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 23,333 | $1.0M | 6/24/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 23,333 | $930K | 5/16/2022 | View on chart |
| RPRX | ▼ Sell | Other | 70,000 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.